喹硫平与氯氮平治疗女性精神分裂症对照研究

目的：探讨喹硫平与氯氮平治疗女性精神分裂症的临床疗效和安全性。方法将86例女性精神分裂症患者随机分为两组，分别口服喹硫平与氯氮平治疗，观察8周。采用阳性与阴性症状量表评定临床疗效、副反应量表评定不良反应。结果治疗8周末喹硫平组总有效率为88．4％，氯氮平组为86．0％，两组比较差异无显著性（χ^2＝0．10，P＞0．05）；喹硫平组不良反应较轻微，其中嗜睡、月经紊乱、泌乳、体质量增加、心电图及脑电图异常等不良反应发生率显著低于氯氮平组（P＜0．05）。结论喹硫平与氯氮平治疗女性精神分裂症疗效显著且相当，但喹硫平对女性内分泌的影响甚微，不增加体质量，更适用于女性精神分裂症患者。

A control study of quetiapine versus clozapine in the treatment of female schizophrenia

Objective To investigate the clinical efficacy and safety of quetiapine and clozapine in the treatment of female schizophrenia .Methods Eighty-six female schizophrenics were randomly divided into two groups of 43 ones each ,they took orally quetiapine and clozapine respectively for 8 weeks .The clinical efficacies were assessed with the Positive and Negative Syndrome Scale （PANSS） and adverse reactions with the Treatment Emergent Symptom Scale （TESS） .Results At the end of the 8th week ,total effective rate was respectively 88 .4% in quetiapine and 86 .0% in clozapine group ,which showed no significant difference （P〉0 .05） .Adverse reactions of quetiapine group were mild and the incidences of such adverse reactions were significantly lower compared with clozapne as lethargy ,menstrual disorder ,lactation ,weight gain ,abnormal ECG and EEG （P〈0 .05） .Conclusion Quetiapine has an evident effect equivalent to clozapine in the treatment of female schizophrenia ,but the former does smaller influence on female endocrine , doesn’t raise body mass ,and is more suitable for female schizophrenics .